Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,970.00
-150.00 (-1.48%)
Sep 19, 2025, 3:30 PM KST

Oncocross Statistics

Total Valuation

Oncocross has a market cap or net worth of KRW 119.82 billion. The enterprise value is 103.86 billion.

Market Cap119.82B
Enterprise Value 103.86B

Important Dates

The next estimated earnings date is Monday, November 10, 2025.

Earnings Date Nov 10, 2025
Ex-Dividend Date n/a

Share Statistics

Oncocross has 12.02 million shares outstanding. The number of shares has increased by 15.69% in one year.

Current Share Class 12.02M
Shares Outstanding 12.02M
Shares Change (YoY) +15.69%
Shares Change (QoQ) +0.23%
Owned by Insiders (%) 27.15%
Owned by Institutions (%) 11.05%
Float 6.60M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 115.40
PB Ratio 6.98
P/TBV Ratio 7.00
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -13.56
EV / Sales 100.03
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -13.75

Financial Position

The company has a current ratio of 14.88, with a Debt / Equity ratio of 0.02.

Current Ratio 14.88
Quick Ratio 14.81
Debt / Equity 0.02
Debt / EBITDA n/a
Debt / FCF -0.05
Interest Coverage -268.96

Financial Efficiency

Return on equity (ROE) is -49.39% and return on invested capital (ROIC) is -32.00%.

Return on Equity (ROE) -49.39%
Return on Assets (ROA) -30.09%
Return on Invested Capital (ROIC) -32.00%
Return on Capital Employed (ROCE) -46.98%
Revenue Per Employee 33.49M
Profits Per Employee -247.14M
Employee Count 31
Asset Turnover 0.06
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 9,707.60
200-Day Moving Average n/a
Relative Strength Index (RSI) 53.74
Average Volume (20 Days) 100,716

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Oncocross had revenue of KRW 1.04 billion and -7.66 billion in losses. Loss per share was -682.54.

Revenue1.04B
Gross Profit 758.82M
Operating Income -8.10B
Pretax Income -7.66B
Net Income -7.66B
EBITDA -7.59B
EBIT -8.10B
Loss Per Share -682.54
Full Income Statement

Balance Sheet

The company has 16.34 billion in cash and 373.60 million in debt, giving a net cash position of 15.96 billion or 1,328.20 per share.

Cash & Cash Equivalents 16.34B
Total Debt 373.60M
Net Cash 15.96B
Net Cash Per Share 1,328.20
Equity (Book Value) 17.16B
Book Value Per Share 1,436.06
Working Capital 15.36B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.47 billion and capital expenditures -1.08 billion, giving a free cash flow of -7.56 billion.

Operating Cash Flow -6.47B
Capital Expenditures -1.08B
Free Cash Flow -7.56B
FCF Per Share -628.70
Full Cash Flow Statement

Margins

Gross Margin 73.09%
Operating Margin -780.61%
Pretax Margin -737.92%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Oncocross does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -15.69%
Shareholder Yield n/a
Earnings Yield -6.39%
FCF Yield -6.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Oncocross has an Altman Z-Score of 61.72 and a Piotroski F-Score of 4.

Altman Z-Score 61.72
Piotroski F-Score 4